Korea, China distributors for Cytori

October 2007
Medical Device Daily;10/18/2007, Vol. 11 Issue 200, p8
The article reports that San Diego, California-based Cytori Therapeutics has expanded its Asia-Pacific distribution network for the Celution system in reconstructive surgery with the addition of Olympus Digital Networks Korea to cover South Korea and Shanghai Cosmo Medical Products to cover China. According to Cytori, the new distributors will guide and support regulatory clearances, oversee product sales and provide physician education and training in their respective countries.


Related Articles

  • BREAST RECONSTRUCTION STUDY INITIATED IN JAPAN.  // Worldwide Biotech;Jun2006, Vol. 18 Issue 6, p3 

    Reports on the plan of Cytori Therapeutics Inc. to conduct a breast reconstruction study in Japan. Efficacy of using adult adipose derived stem and regenerative cells for breast reconstruction; Use of the company's Celutionâ„¢ system to isolate and concentrate patient stem and regenerative...

  • Revenues From Stem Cell Therapies to Double in 2007, Predicts Expert. Weeks, Katie // San Diego Business Journal;2/19/2007, Vol. 28 Issue 8, p14 

    The article reports on the forecast that revenues earned from stem cell therapies will grow in 2007. According to a research by medical industry analyst Robin Young and consulting firm RRY Publications, sales of stem cell products in the U.S. has reached $16.4 million and will double to $35...

  • Cytori gets protection for stem/regenerative cell tech.  // Medical Device Daily;6/12/2008, Vol. 12 Issue 113, p4 

    The article reports on the receipt of Notification of Issuance by Cytori Therapeutics from the U.S. Patent & Trademark Office for its core patent covering the Celution System. Patent No. 7,390,484 protects key device technology of Cytori, which processes adult stem and regenerative cells from...

  • Financings roundup.  // Medical Device Daily;6/15/2010, Vol. 14 Issue 114, p2 

    This article reports on the 20 million U.S. dollar loan facility secured by Cytori Therapeutics from GE Capital, Healthcare Financial Services, Oxford Finance Corp. and Silicon Valley Bank.

  • Cytori begins cell therapy study in Japan.  // Medical Device Daily;10/29/2012, Vol. 16 Issue 209, p8 

    The article reports on the approval by the Japan Ministry of Health, Labor and Welfare on two independent investigator-sponsored and funded cell therapy clinical studies of Cytori Therapeutics in the country.

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that the study on autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery was published by Cytori Therapeutics Inc. in the "Journal of Surgical Oncology."

  • Financings roundup.  // Medical Device Daily;10/11/2010, Vol. 14 Issue 197, p3 

    The article reports on the decision of San Diego, California-based Cytori Therapeutics to sell 4 million shares of its common stock for 4.50 U.S. dollar per share.

  • Cytori Pursuing Restructuring Plan. Meiling, Brittany // San Diego Business Journal;9/29/2014, Vol. 35 Issue 39, p9 

    The article reports that San Diego-based cell therapy firm Cytori Therapeutics Inc. has planned to pursue its corporate restructuring plan.

  • Cytori receives expanded approval for Celution.  // Medical Device Daily;7/29/2010, Vol. 14 Issue 146, p8 

    The article reports that an expanded European approval was received by Cytori Therapeutics via a CE mark for its Celution system, a device that extracts and separates stem and regenerative cells from a patient's own fat tissue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics